Literature DB >> 30445174

Jet nebulization of bacteriophages with different tail morphologies - Structural effects.

Sharon Shui Yee Leung1, Nicholas B Carrigy2, Reinhard Vehring2, Warren H Finlay2, Sandra Morales3, Elizabeth A Carter4, Warwick J Britton5, Elizabeth Kutter6, Hak-Kim Chan7.   

Abstract

It was previously demonstrated that the loss of infectivity of a myovirus PEV44 after jet nebulization was closely related to a change in bacteriophage (phage) structure. In this follow-up study, we further examined the impact of jet nebulization on tailed phages, which constitute 96% of all known phages, from three different families, Podoviridae (PEV2), Myoviridae (PEV40) andSiphoviridae (D29). Transmission electron microscopy (TEM) identified major changes in phage structures after jet nebulization, correlating with their loss of infectivity. For the podovirus PEV2, jet nebulization had a negligible impact on its activity (0.04 log10 pfu/mL loss) and structural change. On the other hand, the proportion of intact phages in the nebulized samples dropped from 50% to ∼27% for PEV40 and from 15% to ∼2% for D29. Phage deactivation of PEV40 measured by the TEM structural damage (0.52 log10 pfu/mL) was lower than that obtained by plaque assay (1.02 log10 pfu/mL), but within the range of variation (±0.5 log10 pfu/mL). However, TEM quantification considerably underestimated the titer reduction of D29 phage, ∼2 log pfu/mL lower than that obtained in plaque assay (3.25 log10 pfu/mL loss). In conclusion, nebulization-induced titre loss was correlated with morphological damage to phages and in particular, the tail length may be an important consideration for selection of phages in inhaled therapy using jet nebulization.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Cryo-TEM; Drug-resistance; Nebulizer; Phage; Pulmonary infections

Mesh:

Year:  2018        PMID: 30445174     DOI: 10.1016/j.ijpharm.2018.11.026

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  10 in total

1.  Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Mengyu Li; Yuncheng Wang; Yu Lin; Sandra Morales; Andrew J McLachlan; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

2.  Nebulized Bacteriophage in a Patient With Refractory Mycobacterium abscessus Lung Disease.

Authors:  Rebekah M Dedrick; Krista G Freeman; Jan A Nguyen; Asli Bahadirli-Talbott; Mitchell E Cardin; Madison Cristinziano; Bailey E Smith; Soowan Jeong; Elisa H Ignatius; Cheng Ting Lin; Keira A Cohen; Graham F Hatfull
Journal:  Open Forum Infect Dis       Date:  2022-04-12       Impact factor: 4.423

Review 3.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

4.  Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.

Authors:  Nicholas B Carrigy; Sasha E Larsen; Valerie Reese; Tiffany Pecor; Melissa Harrison; Philip J Kuehl; Graham F Hatfull; Dominic Sauvageau; Susan L Baldwin; Warren H Finlay; Rhea N Coler; Reinhard Vehring
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

5.  Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.

Authors:  Mengyu Li; Rachel Yoon Kyung Chang; Yu Lin; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

6.  Bacteriophage-Loaded Poly(lactic-co-glycolic acid) Microparticles Mitigate Staphylococcus aureus Infection and Cocultures of Staphylococcus aureus and Pseudomonas aeruginosa.

Authors:  Pranav P Kalelkar; Dina A Moustafa; Milan Riddick; Joanna B Goldberg; Nael A McCarty; Andrés J García
Journal:  Adv Healthc Mater       Date:  2022-01-07       Impact factor: 11.092

Review 7.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

8.  Characterization and Genome Study of Novel Lytic Bacteriophages against Prevailing Saprophytic Bacterial Microflora of Minimally Processed Plant-Based Food Products.

Authors:  Michał Wójcicki; Paulina Średnicka; Stanisław Błażejak; Iwona Gientka; Monika Kowalczyk; Paulina Emanowicz; Olga Świder; Barbara Sokołowska; Edyta Juszczuk-Kubiak
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

Review 9.  Pulmonary Delivery of Emerging Antibacterials for Bacterial Lung Infections Treatment.

Authors:  Jiaqi Li; Huangliang Zheng; Sharon Shui Yee Leung
Journal:  Pharm Res       Date:  2022-09-19       Impact factor: 4.580

Review 10.  Phage Therapy for Multi-Drug Resistant Respiratory Tract Infections.

Authors:  Joshua J Iszatt; Alexander N Larcombe; Hak-Kim Chan; Stephen M Stick; Luke W Garratt; Anthony Kicic
Journal:  Viruses       Date:  2021-09-11       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.